Activating mutants of ras are among the most frequently found genetic alterations in human cancers. Therefore, Ras appears to be an attractive target for therapeutic intervention using gene transfer. The protein kinase Raf-1 acts as a direct downstream effector of Ras and is involved in Ras-induced cellular transformation. Using the NIH3T3 fibroblast-derived tumor cell line PEJ, which expresses oncogenic Ha-ras G12V , we analyzed whether dominant negative mutants of Raf-1 can inhibit Ras-mediated transformation. Retroviral gene transfer was used to stably transduce PEJ cells with three different dominant negative mutants of Raf-1. This resulted in reversion of the transformed phenotype in vitro as evidenced by an increase in contact inhibition and reduced anchorage-independent growth. However, tumor formation in nude mice was significantly delayed only by one of these mutants. Therefore, dominant negative mutants of the oncoprotein Myc, which is known to synergize with Raf-1 in tumor formation, were transduced into PEJ cells expressing a dominant negative Raf mutant. This leads to killing of the cells. These results indicate that although interference with Ras-induced transformation using dominant negative mutants of Raf is feasible and effective in vitro using retroviral vectors, an additional block (e.g., that of Myc) is necessary to kill PEJ cells. These results also indicate that interference with Ras-dependent signaling is not sufficient for inhibition of tumor formation of PEJ cells in vivo. Cancer Gene Therapy (2000) 7, 697-706
M
any human neoplastic diseases are associated with activating mutations in ras genes. 1 Therefore, Ras oncoproteins appear to be suitable targets for therapy using genetic approaches. One immediate downstream effector of Ras is Raf-1, the cellular homolog of the viral oncogene v-raf, which is encoded by the murine sarcoma virus strain 3611. Both Raf-1 and v-Raf exhibit serine/ threonine protein kinase activity. 2, 3 Raf-1 contains three conserved regions (CR1-CR3) that are found in all known Raf proteins ( Fig 1A) . CR1, located within the N-terminal part of the protein, contains a cysteine-rich zinc-finger region and is involved in the binding of the activated guanosine triphosphate (GTP)-bound form of Ras. CR2 is rich in serine and threonine residues. It contains conserved S259, which is a major in vivo phosphorylation site and is involved in the binding of the regulatory protein 14-3-3. 4 -7 CR3 in the C-terminal portion contains the catalytic domain. After growth factor stimulation of quiescent cells, the activated GTP-bound form of Ras directly interacts with Raf-1 and thereby recruits Raf-1 from the cytoplasm to the plasma membrane, where it is activated by additional events. 8, 9 Activated Raf-1 phosphorylates mitogen-activated protein (MAP) kinase kinase (MAPKK) or MAP kinase extracellular signal-related kinase (ERK) kinase (MEK), which in turn phosphorylates ERK1 and ERK2, which are members of the MAP kinase (MAPK) family. 9 ERKs phosphorylate cytoplasmic substrates as well as nuclear transcription factors. 10 Recently, it has been shown that positive as well as negative feedback regulation of Raf involves MEK and ERK. [11] [12] [13] Expression of oncogenic Ras mutants that are constitutively activated because of a defect in the intrinsic GTPase activity results in activation of the Ras signaling pathway without stimulation of the cells by mitogens or growth factors. Activated Ras can stimulate both the expression of early response genes such as c-myc and c-fos and DNA synthesis via the Raf/MEK/ERK kinase cascade.
14 Furthermore, expression of oncogenic Ras leads to a transformed phenotype of fibroblast cell lines that is characterized by loss of contact inhibition, decreased growth factor requirements, substrate-independent growth, and persistent membrane ruffling, as well as tumor formation in mice. 15, 16 The dominant negative Ras mutant, Ras S17N , which is locked into the guanosine diphosphate-bound inactive conformation, inhibits serum-induced DNA synthesis and receptor tyrosine kinase-induced growth and differentiation pathways. In addition, the transformed phenotypes of a variety of human tumor cell lines can be reverted by expression of Ras S17N . 17 The inhibitory effect of the Ras S17N mutant can be overcome by oncogenic v-Raf. 18 Previously, it has been shown that a c-raf-1 antisense RNA or kinasedefective Raf-1 mutants can interfere with Ras-induced transformation in NIH3T3 fibroblasts. 19 Furthermore, c-raf-1 antisense oligodeoxynucleotides can delay tumor formation in mice when given intravenously. 20 Also, ) were lysed at 3 weeks (lanes 1-4), 6 weeks (lanes 5, 6, 8, and 9), or 19 weeks (lanes 7 and 10) posttransduction as described in Materials and Methods. Raf proteins were immunoprecipitated using Raf-1-specific antisera directed against the amino terminus (␣NT) or the carboxyl terminus (␣CT) as indicated. Proteins were immunoblotted with the anti-FLAG Ab and visualized using the ECL detection system. Lysates of cells transduced with the LXSN vector (lanes 1, 5, and 8) and lysates of cells expressing FLAG-Raf(K375E) (lanes 2, 9, and 10), FLAG-Raf(1-331) (lanes 3, 6, and 7), and FLAG-Raf(1-257) (lane 4) were analyzed. Molecular masses in kilodaltons are indicated on the left. Lysates of cells transduced with LXSN (lane 11) or cells expressing FLAG-Raf(K37E) (lane 12) were immunoprecipitated and immunoblotted with anti-Raf carboxyl terminus antiserum (␣CT) to assess the amount of the overexpressed full-length Raf mutant over the endogenous Raf. C: Immunofluorescence staining of PEJ cells expressing dominant negative Raf-1. PEJ cells transduced with the LXSN vector as a control (b) and those expressing FLAG-Raf(K375E), FLAG-Raf(1-331), and FLAG-Raf(1-257) (d, f, and h, respectively) were stained using the anti-FLAG mAb M2 as described in Materials and Methods. Interference contrast images of the same cells are shown on the left (a, c, e, and g, respectively).
inhibitors of Ras farnesylation and a single chain fragment (scFv) of a Ras-neutralizing monoclonal antibody (mAb) have been used to promote tumor regression in mouse systems. 21, 22 In addition to Raf-1, an increasing number of other Ras effectors have been identified. These comprise especially phosphatidylinositol-3-kinase, the Ral guanine nucleotide dissociation stimulator, as well as the GTPase-activating proteins p120 GAP and neurofibromin-1. 23 Rac and Rho, which are members of the Rho family of small G proteins, also act downstream of Ras, are involved in the control of actin organization and cellular morphology, and synergize with the Ras/Raf/ MEK/ERK pathway in cellular transformation. 24 In addition, Ras and Raf-1 can synergize with the transcription factor c-Myc in cellular transformation and in inducing cell cycle progression. [25] [26] [27] Indeed, the highly oncogenic retrovirus MH2 codes for v-Mil, which is the avian homolog of Raf-1, and v-Myc.
In this study, we assessed the transformation-suppressive potential of three dominant negative mutants of Raf-1 in a Ha-ras-transformed NIH3T3 fibroblast model cell line (PEJ), which expresses the oncogenic genomic clone Ha-Ras
G12V
. Retroviral vectors were used to transduce the cDNA encoding the dominant negative Raf mutants. This resulted in increased contact inhibition, in a reduction of anchorage-independent growth, and in a partial inhibition of hyperphosphorylation of ERK2, whereas cell proliferation was not influenced. Tumor formation in nude mice was significantly reduced in tumor cells expressing one of the Raf mutants but unaffected by the others. A combination of the dominant negative mutants of Raf-1 and of Myc abolished cell growth and led to cell death. We conclude that interfering with Ras signal transduction pathways using dominant negative Raf mutants is a feasible way to reduce tumor formation. However, it appears that this method is not sufficient to abolish tumor formation completely or to kill the tumor cells. Thus, at least in the PEJ cells investigated here, additional blocking molecules such as dominant negative Myc are necessary.
MATERIALS AND METHODS

Construction of retroviral vectors encoding dominant negative Raf-1 mutants
The FLAG epitope encoding sequence proceeded by an optimal Kozak translation initiation sequence was cloned 5Ј to the human c-raf-1 cDNA inserted in pUC18. The retroviral vector LFR(1-257)SN was obtained by inserting the 812-bp EcoRI/SalI fragment from pUC-FLAG-Raf into the EcoRI/ HpaI sites of the LXSN vector. 28 Similarly, LFR(1-331)SN was generated by inserting the 1037-bp EcoRI/StuI fragment from pUC-FLAG-Raf into the EcoRI/HpaI sites of LXSN. In both constructs, in frame stop codons had to be introduced. Vector sequences lead to the addition of 10-and 7-aa residues in LFR(1-257)SN and LFR(1-331)SN, respectively. The vector LFR(K375E)SN is similar to the constructs described above, but encodes full-length Raf-1 with an exchange of lysine 375 to glutamic acid. The dominant negative Myc constructs containing an insertion of four serine residues (MycIn373) and a deletion in the transactivation domain (MycD106 -143) have been described previously. 29 
Generation of transient and stable retroviral vector producer cells (VPCs)
The GP ϩ E-86 and BOSC 23 packaging cell lines were cultured in selection medium at 37°C and 5% CO 2 . 30, 31 The PEJ cell line is identical with the NIH pEJ cl3 cell line and was a kind gift from Dr. R. Schaefer (Humboldt University, Berlin, Germany). 32 The cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine sera, 100 U/mL penicillin, 100 g/mL streptomycin, and 2 mM Lglutamine (complete medium) at 37°C and 5% CO 2 . At 2 days before transfection, packaging cell lines were cultured in complete medium. On day 0, 2 ϫ 10 6 BOSC 23 cells were plated into a 6-cm dish. On the following day, 10 g of the retroviral vector DNA was transfected using the calcium phosphate coprecipitation method. On days 2-3, when the cells were confluent, the medium was reduced to 2 mL and the cells were grown at 32°C, 5% CO 2 . On the following day, retroviral supernatants were harvested and filtered through a 0.45-m filter. Virus stocks were stored at Ϫ70°C.
Stable retroviral producer cells were obtained by infecting 10 5 GP ϩ E-86 cells that had been cultured in complete medium supplemented with tunicamycin (100 ng/mL) for 18 hours in the presence of polybrene (8 g/mL). Infected cells were selected by adding G418 to the culture medium (1 mg/mL). To harvest retroviral vector particles, confluent VPCs in a 10-cm dish were cultured for 18 hours in 5 mL of medium at 32°C, and the supernatant was processed as described above. To test for the presence of replication-competent retrovirus, marker rescue assays were performed using NIH3T3tk Ϫ cells that had been transduced with the MFG-lacZ vector as marker-containing cells, similarly as described previously. 28 With this test, we did not detect replication-competent retrovirus in our vector preparations.
Expression of dominant negative mutants of Raf-1 in PEJ cells
A total of 10 5 PEJ cells were transduced by incubation in 10 mL of retroviral supernatant in the presence of polybrene (8 g/mL) for 18 hours. This procedure was repeated two to three times to favor multiple retroviral integrations. From day 1 posttransduction, G418 (1 mg/mL) was added to the medium to select for transduced cells. To test for the expression of Raf-1 mutants, 10 7 cells of each line were lysed in RIPA buffer, 33 and Raf proteins from the supernatants were immunoprecipitated using the rabbit anti-Raf serum 1617 (anti-CT) and 1657 (anti-NT). 33 Immunocomplexes were separated on a 10% sodium dodecyl sulfate polyacrylamide gel and blotted to a nitrocellulose membrane. Immunodetection was carried out with the anti-FLAG mAb M2 (IBI/Kodak, New Haven, Conn) and the enhanced chemiluminescence (ECL) detection system (Amersham, Braunschweig, Germany). Protein expression was verified by immunoblot 4 weeks later. For indirect immunofluorescence studies, cells were fixed in 3% paraformaldehyde and permeabilized using 0.5% Triton X-100. Detection of the FLAG-tagged Raf proteins was done using the M2 mAb diluted 100-fold and a tetramethylrhodamine B isothiocyanateconjugated goat anti-mouse serum (Sigma, Buchs, Switzerland). Immunofluorescence of the samples was recorded using a Zeiss Axioplan microscope (Zeiss, Oberkochen, Germany) confocal imaging system equipped with a Bio-Rad MRC 600 (Bio-Rad, Glattbrugg, Switzerland).
Assessment of the transformed phenotype of transduced PEJ cells in vitro
PEJ cells spontaneously form foci in standard tissue culture. This phenotype was quantitated by counting the number of foci containing Ͼ20 cells per focus of the identically treated different transduced cell lines per low power field (ϫ36). Cells were scored as ϩϩϩ, ϩϩ, or ϩ, if they showed Ͼ20, 1-20, or Ͻ1 focus per low power field, respectively. To determine the generation times of the cell lines, 10 5 cells were plated into a 6-cm dish (15 dishes per cell line) and grown in complete medium without G418. The medium was changed every other day. Cell counts were determined every day in triplicate. For the soft-agar assays, 5 ϫ 10 4 cells were plated in 0.3% agar in complete medium on top of a bottom layer of 0.5% agar in 6-well plates. Colony numbers per low power field were counted on day 12.
ERK2 immunoblot
Cells were starved for 6 hours. After washing with ice-cold phosphate-buffered saline (PBS), the cells were lysed in 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.5), 1 mM ethyleneglycol-bis(-aminoethyl ester)-N,N,NЈ,NЈ-tetraacetic acid, 10 mM MgCl 2 , 2 mM MnCl 2 , 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 20 kallikrein inhibitor units/mL aprotinin (Trasylol; Bayer, Wuppertal, Germany), and 1 mM leupeptin by passing them 10 times through a 25-gauge needle. The lysates were clarified by centrifugation, and aliquots were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to a nitrocellulose membrane which subsequently was probed with a polyclonal ERK2 antibody (Ab) (Upstate Biotechnology, Lake Placid, NY). ERK2 was visualized with the ECL detection system (Amersham).
Flow cytometry analysis
Cells at 80 -90% confluency were harvested, washed in PBS, and fixed in 70% ethanol. DNA contents were determined using a fluorescence-activated cell sorter (Becton Dickinson, Mountain View, Calif) after ribonuclease treatment and staining with propidium iodide (40 g/mL) for 30 minutes at 37°C. To test for apoptotic and nonapoptotic cell death, PEJ cells and cells expressing FLAG-Raf(1-331) were transduced five times with virus encoding dominant negative mutants of c-Myc and analyzed by double staining with fluorescein isothiocyanate-labeled annexin V and propidium iodide. 34 
Tumor formation in nude mice
We purchased 4-to 6-week-old ICR nu/nu mice from the Institute of Laboratory Animal Sciences (University of Zurich). For tumor formation tests, animals were anesthetized using methoxyflurane, and 10 6 cells in 200 L of PBS were injected subcutaneously into the right flanks. Tumor sizes were determined every other day by measuring the largest (a) and the perpendicular diameter thereof (b) of each tumor and calculating the volume using the following formula: V ϭ ([a ϫ b 2 ]/2). Tumors were scored positive if they were Ͼ10 mm 3 . Animals had to be sacrificed when the tumor size exceeded 20 mm in diameter or if skin ulcerations were observed. Statistical analysis was performed using the Wilcoxon-Mann-Whitney rank sum test, and P values for the one-sided analysis were determined. All animal experiments were carried out according to Swiss federal law and were supervised by the local authorities (Kantonales Veterinäramt, Zürich, Switzerland).
RESULTS
Transduction of PEJ cells with retroviral vectors encoding dominant negative Raf mutants
The PEJ cell line is based on NIH3T3 fibroblasts that have been stably transfected with plasmid DNA containing an activated Ha-ras G12V gene under the control of its own promoter. 32 It has been shown that these cells possess a highly transformed phenotype, including the ability to form tumors in mice. To test how the stable expression of dominant negative mutants of Raf-1 would affect the transformed phenotype of these cells, the corresponding cDNAs were cloned into recombinant retroviruses based on the LXSN vector ( Fig 1A) and transduced into PEJ cells. The construct, designated as LFR(K375E)SN, encodes a mutated FLAG-tagged Raf-1 protein in which lysine 375 is changed to glutamic acid. This amino acid exchange lies within the adenosine triphosphate binding site and inactivates the protein kinase. It acts as a dominant inhibitor of the MAPK pathway in Xenopus laevis oocytes (our unpublished results). The constructs LFR(1-331)SN and LFR(1-257)SN encode mutants comprising amino acid residues 1-331 and 1-257, respectively. The FLAG epitope did not interfere with Ras binding, because all mutants were able to bind Ras as shown by coimmunoprecipitation from transfected cells (data not shown). In addition, two dominant negative mutant constructs of c-myc, a deletion mutant within the transactivation domain (MycD106 -143) and a linker insertion mutant just Cterminal to the DNA-binding basic region (MycIn373) were used (Fig 1A) . 29 Retroviral VPCs were generated by transfecting the retroviral vector constructs into the ecotropic packaging cell line BOSC 23 using the calcium phosphate coprecipitation method. 30 Recombinant retroviral particles were harvested as described in Materials and Methods. To obtain stable VPCs, the supernatants were used to transduce the packaging cell line GP ϩ E-86 after treatment with tunicamycin (100 ng/mL) for 18 hours before transduction. 31 Transduced cells were selected and maintained as pools in growth medium containing G418 (1 mg/mL). All Raf and Myc constructs were allowed to establish stable VPCs. The supernatants from the different VPCs were used to transduce PEJ cells in vitro. Cells transduced with Raf or Myc mutants were selected by the addition of G418 (1 mg/mL) to the culture medium, which did not cause a severe cellular crisis, indicating a high transduction efficiency.
Characterization of cells expressing dominant negative Raf-1 mutants
The transduced cell lines were analyzed for Raf-1 expression by immunoprecipitation and immunoblotting using the Raf-1 N terminus-specific rabbit antiserum (anti-NT) and the anti-FLAG mAb M2, respectively. As shown in Figure 1B (lanes 1-4) , the transduced cells expressed the Raf-1 mutant proteins of the expected apparent molecular masses. Expression was monitored over an extended period of culturing time. No significant changes were detected over 19 weeks (Fig 1B, lanes 7  and 10) . The expression levels of the dominant negative Raf-1 mutants were ϳ10-fold higher than that of endogenous Raf-1, as shown for FLAG-Raf (K375E) using an antiserum directed against the C terminus of Raf-1 (anti-CT) (Fig 1B, lanes 11 and 12) .
Indirect immunofluorescence studies using the anti-FLAG Ab were performed to verify the expression of the mutant proteins at the level of individual cells ( Fig  1C) . As can be seen, in comparison with the interference contrast microscopy pictures (Fig 1C, panels c, e, and g ), all cells expressed detectable levels of dominant negative Raf mutant proteins (Fig 1C, panels d, f, and h) .
Cells stably transduced with recombinant retroviruses encoding the three dominant negative Raf-1 mutants were analyzed in vitro. PEJ cells have lost contact inhibition and form large foci under standard tissue culture conditions, whereas those cells expressing dominant negative Raf-1 mutants have a markedly reduced tendency to grow as foci, especially with the two deletion mutants, which show a 20-fold reduction in focus formation compared with the untransduced cells and vector controls (Fig 2, Table 1 ).
In vitro growth kinetics of PEJ cells expressing dominant negative Raf
To further characterize the transduced cells, their growth kinetics were determined after selection with G418. The growth kinetics of the stably transduced cells are shown in Figure 3 . Under standard culture conditions (10% fetal calf serum (FCS)), no difference in the growth kinetics among the transduced and nontransduced cell lines was detected (Fig 3) . Similarly, under low-serum conditions (0.5% FCS), cell growth was slowed equally in transduced cells as well as in vector controls (data not shown). Flow cytometry analyses of cells expressing FLAG-Raf(1-331) showed that the distribution of the various phases of the cell cycle were similar compared with the vector control (see Fig 6, a  and b ).
Reduced hyperphosphorylation of ERK2 in PEJ cells expressing dominant negative mutants of Raf
Because Ras can act through the Raf/MEK/ERK kinase cascade, the effect of the dominant negative Raf proteins on signal transduction to the downstream effector ERK2 was determined. ERK2 activity correlates with hyperphosphorylation and reduced electrophoretic mobility (Fig 4) . In PEJ cells, most ERK2 is found in its hyperphosphorylated slower migrating state, even after serum starvation of the cells, which is due to persistent activation by the constitutively activated Ha-Ras protein.
However, in serum-starved PEJ cells expressing the dominant negative Raf-1 mutants FLAG-Raf(1-331) and FLAG-Raf(K375E), most ERK2 is in its unphosphorylated form, indicating inhibition of the ERK2 kinase activity and of this signaling pathway (Fig 4, lanes  1-3) . Epidermal growth factor (EGF) stimulation of cells expressing the mutant Raf results in only partial activation of ERK2 (Fig 4, lanes 4 -6) . PEJ cells expressing the Raf-1 mutant FLAG-Raf(1-257) showed no significant effect on the hyperphosphorylation of ERK (data not shown). These data indicate that expression of two of three Raf-1 mutants can reduce the Ras-induced ERK2 hyperphosphorylation but still allow cell proliferation.
Tumor formation in nude mice
To analyze tumor formation in an animal model, 10 6 cells of each of the three lines stably expressing Raf mutant proteins and control lines were injected into the right flanks of 4-to 6-week-old athymic nude mice. Nude mice instead of syngeneic animals were chosen to minimize potential immunological reactions toward the transgene products. Cells expressing FLAG-Raf(1-331) led to reduced tumor formation (Fig 5) . On day 23 after injection of the tumor cells, the average tumor size in this group was about one-third of that seen for the control groups. Statistical analysis using the WilcoxonMann-Whitney rank sum test showed a difference between the groups injected with FLAG-Raf(1-331)-expressing PEJ cells (n ϭ 9) and nontransduced (n ϭ 5, P Ͻ .025) or mock-transduced (n ϭ 7, P Ͻ .05) PEJ cells, respectively. In contrast, differences between the two other lines (PEJ/LFR(1-257)SN and PEJ/ LFR(K375E)SN) and the controls were not statistically significant. The experiment was terminated on day 23 because of the beginning of skin ulcerations in some animals. The PEJ cells expressing FLAG-Raf(1-331) also showed the most prominent reversion of the transformed phenotype in vitro (Table 1, Fig 2) . However, the capacity for tumor formation of even these cells was not completely suppressed, because the same tumor sizes as seen in the other groups were reached with a delay of ϳ8 days.
Effects of dominant negative Myc mutants
The fact that a delay in tumor formation was achieved by only one of the dominant negative mutants of Raf and the unimpaired growth kinetics of the PEJ cell lines expressing the three dominant negative Raf mutants suggested the involvement of an additional pathway in sustaining the transformed phenotype. Because Ras/Raf and Myc synergize in tumor formation and cell cycle progression, [25] [26] [27] we anticipated that a dominant negative Myc mutant should be able to stop proliferation in conjunction with dominant negative Raf mutants.
Two Myc mutants were used that have been described previously as functioning as dominant negative proteins (Fig 1A) . 29 The deletion mutant in the transactivation domain, MycD106 -143, and the linker insertion mutant just C-terminal to the DNA-binding basic region, MycIn373, leave the helix-loop-helix and leucine zipper domains intact. Thus, they can form nonfunctional complexes with Myc-binding proteins such as Max. This would decrease or abolish the ability of the Myc-binding partner(s) to form functional complexes with endogenous Myc. The protein expression of the retrovirally transduced Myc mutants MycD106 -143 or MycIn373 was at least five times above the endogenous level of c-Myc as verified by immunoblotting (data not shown). However, in PEJ cells, expression of these dominant negative mutants had no effect on cell growth or cell Tumor diameters were measured every other day from day 5 on. Tumors were scored positive if they were Ͼ10 mm 3 . The average tumor volumes for each group at a given timepoint are shown. Error bars represent SEMs. Tumor sizes were compared using the Wilcoxon-Mann-Whitney rank sum test. In the group that was injected with untransduced cells, one animal had to be sacrificed on day 15 because it had developed ascites, it was excluded from all further analysis.
cycle distribution, nor did it reduce the ability of these cells to form tumors in nude mice (Fig 6, compare a with  c and d; data not shown) . In contrast, transduction of PEJ cells stably expressing dominant negative FLAGRaf(1-331) with a retrovirus encoding MycD106 -143 or MycIn373 leads to deregulation of the normal cell cycle distribution (Fig 6, e and f) . After transduction of FLAG-Raf(1-331)-expressing cells with virus-encoding dominant negative mutants of Myc, ϳ70% of the cells died. This process did not involve apoptosis as tested by double staining with annexin V and propidium iodide (data not shown). Residual cells that were still alive were most likely not transduced by the dominant negative Myc-encoding retroviruses, because further transduction led to the death of all cells (data not shown). Thus, neither transduction of dominant negative Raf nor dominant negative Myc alone is sufficient to completely revert the transformation of PEJ cells. In contrast, cotransduction of both mutants was lethal to these cells. The mechanism by which the coexpression of dominant negative Raf and Myc leads to the death of PEJ cell is currently under investigation.
DISCUSSION
This study analyzes the tumor-suppressive potential of dominant negative mutants of Raf-1 in a Ha-Ras G12V -induced tumor model. Although expression of dominant negative Raf mutants in PEJ cells resulted in an increase in contact inhibition, in a reduction of anchorage-independent growth (as evidenced by soft agar assays), and in a reduction of ERK activity, the proliferation of the PEJ cells was unimpaired. Tumorigenicity in nude mice was significantly affected by only one of the dominant negative Raf mutants, FLAG-Raf(1-331). A blockade of proliferation and an induction of cell death was achieved by additional transduction of dominant negative c-Myc mutants.
Several approaches have been developed to interfere with Ras-induced transformation. Georges at al 35 used retroviral antisense Ki-ras constructs to inhibit tumor formation in an orthotopic in vivo lung cancer model in nude mice. Ogiso et al 17 have shown that dominant negative Ras (Ras S17N ) is able to block transformation in a variety of human tumor cell lines. Inhibition of Ras farnesylation, which prevents localization of Ras to the plasma membrane, is also able to interfere with Rasmediated cellular transformation. 21 A more indirect way to interfere with Ras function is to block its capability to transfer activating signals to its downstream effectors. Recently, a scFv has been used successfully to revert transformation and to induce apoptosis in several human tumor cell lines. 22 This approach was also effective in vivo after adenoviral gene transfer of the scFv-encoding sequence. A previous study showed that transfection of v-Ki-ras-transformed NIH3T3 cells with plasmids coding for dominant negative Raf proteins resulted in a reduction in colony formation; therefore, it was suggested that Raf is an essential signal transducer downstream of Ras. 19 Similarly, the use of antisense constructs or oligodeoxynucleotides targeted against c-raf-1 has been shown to revert the ras-transformed phenotype and reduce cell proliferation in v-raf-transformed cells and various established ras-dependent tumor cell lines. 19, 20 In contrast to the antisense approach, the dominant negative Raf mutants used here are functional Raf knockouts that do not inhibit Raf expression but compete with the endogenous Raf protein for activators such as Ras. Moreover, overexpression of dominant negative mutants of Raf-1 titrates out activated Ras, which consequently can no longer mediate signals to other effector molecules, such as the Rho family of GTPases that are known to be essential for morphological transformation and have been shown to synergize with Raf in the Ras transformation of NIH3T3 cells. [35] [36] [37] In this study, the tumor growth of the transduced cells was dependent upon the length of the dominant negative Raf mutants. Most efficient was the construct comprising amino acids 1-331 of Raf-1. This mutant includes the Ras binding sites as well as the amino terminal binding site for 14-3-3 comprising serine 259. 38 14-3-3 proteins are adaptor molecules that are involved in negative and positive regulation of the Raf-1 activity. 39 Therefore, FLAGRaf(1-331) may titrate out not only activated Ras but also 14-3-3, which is supposed to be essential for Raf-1 activation. The Raf-1 mutant FLAG-Raf(1-257) contains the Ras binding site but no 14-3-3 binding site, which may explain why this mutant did not interfere significantly with the ERK phosphorylation and tumor formation of PEJ cells. The full-length Raf kinase dead mutant FLAG-Raf(K375E) can still bind 14-3-3, but interaction with other proteins is hindered because of a closed conformation of the inactive Raf-1 protein. 39 This could explain the results indicating that FLAGRaf(K375E) was less efficient than FLAG-Raf(1-331) but had a more pronounced effect than FLAG-Raf (1-257) .
Recently, it has been shown that a Raf-derived peptide containing the amino acid residues 143-150 involved in interaction with Ras not only inhibits Rasmediated activation of Raf-1 but also blocks the neurofibromin-1-induced stimulation of Ras GTPase activity. 40 This demonstrates that the binding of Raf-1 sequences to the Ras effector domain can indeed influence Raf-1-independent pathways. This could explain the fact that dominant negative Raf mutants lead to a substantial reversion of transformation as shown in in vitro tests. It is interesting to note that although expression of dominant negative Raf mutants in PEJ cells resulted in reversion of transformation in vitro, this does not correlate with a loss of tumorigenicity in vivo. Recently, it has been shown that loss of oncogenic Ha-ras in a fibrosarcoma cell line correlates with loss of the transformed phenotype in vitro but not with a loss of tumorigenicity of the cells in nude mice. 41 Thus, Rasindependent pathways can be activated in established Ras-transformed cell lines, leading to tumor formation in vivo. Interestingly, expression of a dominant negative mutant of c-Jun, which is a distant downstream element of Ras, also resulted in maintenance of the transformed phenotype of PEJ cells; however, its expression inhibits the growth of untransformed NIH3T3 cells. 42, 43 Our results obtained in PEJ cells also indicate the contribution of another activated pathway for cell proliferation and tumorigenicity. Because a synergy of class I and II oncogenes, corresponding to cytoplasmic proteins such as Ras and Raf and nuclear transcription factors such as c-Myc, leads to efficient transformation, we anticipated that inhibition of an additional pathway should completely suppress transformation and proliferation. c-Myc has been shown to cooperate with other oncoproteins such as Ras in the transformation of fibroblasts and in the induction of cell cycle progression. [25] [26] [27] Thus, we expected that inhibition of c-Myc in addition to Ras/Raf-1 would lead to a further reversion of transformation and to a block of cell growth. Indeed, dominant negative Myc mutants that were transduced into PEJ cells stably expressing the dominant negative Raf mutant FLAG-Raf(1-331) resulted in cell death by a nonapoptotic pathway. Therefore, it was not possible to establish a cell line from these cells and to perform animal studies with doubly transduced PEJ cells. In contrast, cells that were only transduced with dominant negative mutants of Myc showed an unimpaired proliferation.
The results provided here indicate that dominant negative mutants of Raf and Myc can synergize for induction of cell death, at least in PEJ cells. This effect seems different from the synergy between v-Abl and c-Myc in murine bone marrow cells, where the dominant negative c-Myc mutants (the same as those used here) only modestly affect cell growth but suppress transformation, suggesting that c-Myc is a downstream effector of v-Abl. v-Abl is a cytoplasmic tyrosine kinase that is related to Src. Because Src has been described as increasing Raf signaling in concert with Ras, the two pathways described here could comprise the Ras/Raf/ MEK/ERK pathway on the one hand and Src or Src-like kinases/Myc on the other (Fig 7) . 44 Many human tumors are characterized by expression of activated Ras mutants. As shown here, inhibition of Ras signaling by expression of dominant negative Raf is able to reduce but not to abolish tumor formation in vivo. Therefore, efficient inhibition of tumorigenicity of established tumor cells from the kind described here requires a block in more than one signal transduction pathway (e.g., by the dominant negative mutants Raf and Myc).
